Concord Biotech Limited IPO Review, Date, Price, GMP

Concord Biotech Limited, an India-based biopharma company, holds a major position as a top global developer and manufacturer of select fermentation-based APIs across oncology and immunosuppressants. In Year 2021, Concord Biotech Limited commanded a substantial market share, based on volume, in this domain, delivering its products to over 70 countries which also includes regulated markets such as India, the United States, Europe, and Japan.

Concord Biotech Limited specialises in handling the complex fermentation process, which includes working with microbial strains and cultures, regulating different process parameters, and finally performing several purification procedures. This intricate technical skill, as well as the massive capital commitment necessary, establish major obstacles to entry in the fermentation-based API field, ensuring the company’s long-term advantage.

In 2016, Concord Biotech made a strategic move into the formulations segment, marketing 27 brands across immunosuppressants, nephrology drugs, and anti-infective drugs for critical care in India and emerging markets. The company’s presence spans 20 states and five union territories in India, facilitated by its sales team.

With its focus on research and development, Concord Biotech has established two DSIR-approved R&D units comprising a team of 163 members, including those with doctoral qualifications. The R&D team is actively involved in advancing products, including complex ones, from R&D to commercialization. Furthermore, Concord Biotech offers contract research and manufacturing services, collaborating with third-party pharmaceutical companies for the development of APIs and formulations.

The company serves over 200 customers in more than 70 countries, including reputed names such as Intas Pharmaceuticals Limited and Glenmark Pharmaceuticals Limited. It has forged long-term supply agreements with some of its customers, fostering stable relationships that have lasted for an average of nine years with its top ten customers by revenue.

Concord Biotech Limited IPO Complete Details:

IPO Date04 August 2023 to 08 August 2023
Issue TypeBook Built Issue IPO
Listing AtNSE BSE
Face Value01 Rs. Per Share
Price705 to 741 Rs.
Lot Size20
Issue Size20,925,652 shares (Rs.1,551.00 Cr)
Employee Discount70 Rs. Per Share
Offer For Sale20,925,652 shares (Rs.1,551.00 Cr)
Listing Date18 August 2023

Concord Biotech Limited IPO Timetable:

Opening Date04 August 2023
Closing Date08 August 2023
Allotment11 August 2023
Initiation of Refunds14 August 2023
Credit of Shares to Demat Account17 August 2023
Listing Date18 August 2023
* Date May Change

Company Financial Details:

Period EndedAssetsRevenueProfit After TaxNet WorthBorrowings
31 March 20211,182.55630.75234.89999.3786.35
31 March 20221,312.80736.35174.931,103.2260.59
31 March 20231,513.98888.48240.081,290.0031.24
Amount In Crore

AS OF NOW, the GMP OF Concord Biotech Limited is Around 122 Rs.

Leave a Reply

Your email address will not be published. Required fields are marked *